Acadian Asset Management LLC Has $6.69 Million Stock Position in AtriCure, Inc. $ATRC

Acadian Asset Management LLC boosted its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 4.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 204,423 shares of the medical device company’s stock after purchasing an additional 8,841 shares during the period. Acadian Asset Management LLC owned about 0.41% of AtriCure worth $6,693,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of AtriCure by 1.3% during the first quarter. Vanguard Group Inc. now owns 4,714,371 shares of the medical device company’s stock worth $152,086,000 after buying an additional 61,166 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in AtriCure by 170.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,196,914 shares of the medical device company’s stock worth $70,872,000 after acquiring an additional 1,385,544 shares during the last quarter. Neuberger Berman Group LLC increased its holdings in AtriCure by 26.3% during the 1st quarter. Neuberger Berman Group LLC now owns 1,186,065 shares of the medical device company’s stock valued at $38,365,000 after purchasing an additional 246,877 shares in the last quarter. Nuveen LLC bought a new position in AtriCure in the 1st quarter valued at $30,666,000. Finally, Goldman Sachs Group Inc. boosted its stake in AtriCure by 1.0% in the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after purchasing an additional 8,956 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ATRC shares. Canaccord Genuity Group raised their target price on AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Wall Street Zen upgraded shares of AtriCure from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, October 8th. Needham & Company LLC increased their price target on shares of AtriCure from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 30th. Finally, Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, AtriCure presently has an average rating of “Moderate Buy” and an average price target of $52.22.

AtriCure Trading Up 0.6%

ATRC opened at $33.06 on Thursday. The firm has a 50 day simple moving average of $35.33 and a 200 day simple moving average of $33.96. AtriCure, Inc. has a fifty-two week low of $28.29 and a fifty-two week high of $43.11. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -54.20 and a beta of 1.56. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.94 and a quick ratio of 2.83.

AtriCure (NASDAQ:ATRC) last released its earnings results on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.10. The firm had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.56%. The business’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, sell-side analysts anticipate that AtriCure, Inc. will post -0.6 earnings per share for the current year.

Insiders Place Their Bets

In other AtriCure news, insider Justin J. Noznesky sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $36.30, for a total transaction of $108,900.00. Following the transaction, the insider owned 83,964 shares in the company, valued at approximately $3,047,893.20. This trade represents a 3.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sven Wehrwein sold 5,000 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $37.00, for a total value of $185,000.00. Following the transaction, the director owned 34,374 shares of the company’s stock, valued at $1,271,838. The trade was a 12.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 13,000 shares of company stock valued at $473,900. 3.50% of the stock is owned by insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.